Redcare Pharmacy's New Leadership Navigates a Surge in Prescription Demand

Redcare Pharmacy's Q1 revenue jumps 18% on 55% prescription growth, but heavy capex for a new logistics center pressures margins. New CFO and board aim to balance expansion with profitability.

Redcare Pharmacy's recent annual meeting marked a definitive leadership transition, with shareholders endorsing a complete overhaul of the supervisory board and confirming a new finance chief. This fresh executive team steps into a complex scenario: the company's core prescription business is booming, yet heavy capital expenditures continue to pressure profitability and investor sentiment.

The operational figures provide a strong starting point. Preliminary group revenue for the first quarter surged over 18 percent to 848 million euros. This growth was fueled by an expanding customer base, which now exceeds 14.2 million active users. The standout performer was the prescription medication segment, where sales exploded by 55 percent to 168 million euros, comfortably surpassing market expectations.

This prescription boom could receive a further boost from potential policy changes in Berlin. An expert commission has recommended significantly higher co-payments for prescription drugs, which could see patients paying up to 15 euros per prescription out of pocket. Analysts, including Felix Dennl from Bankhaus Metzler, view this as a clear tailwind for online pharmacies, anticipating that price-sensitive customers will increasingly switch to more affordable online dispensaries. Federal Health Minister Nina Warken has signaled a willingness to advance corresponding initiatives swiftly.

Against this operational strength, the company's ambitious investment program presents a significant counterweight. Management has declared 2026 a peak investment year, centered on a new logistics center in Pilsen, Czech Republic. This facility is designed to increase annual capacity by 15 million packages. The substantial costs associated with this expansion have led the company to lower its medium-term margin target to over five percent, down from a previous goal of over eight percent. For the full year 2026, the board still targets revenue growth of 13 to 15 percent, with an adjusted EBITDA margin of at least 2.5 percent.

The new leadership team is now tasked with balancing this growth-investment equation. Shareholders officially confirmed Hendrik Krampe as the new Chief Financial Officer. Krampe brings two decades of e-commerce expertise, having spent eight years as Finance Director for Amazon's European marketplace and previously holding senior roles at eBay. He succeeds Jasper Eenhorst, who is leaving the company at his own request.

Simultaneously, the supervisory board welcomes three new faces: Anja Hendel, Max Müller, and Peter Schmid von Linstow. They replace outgoing members, including long-standing associate Björn Söder. This renewed governance body will oversee the critical execution phase of the company's strategy.

The stock market reflects the tension between these powerful forces. Over the past year, Redcare's share price has shed approximately 60 percent of its value, recently trading around 50 euros. However, a tentative recovery is underway, with the stock gaining over 30 percent in the last month. Despite this rebound, the share price remains about 27 percent below its level at the start of the year. Analysts are showing cautious optimism; Jefferies has reaffirmed its buy recommendation with a price target of 150 euros.

All eyes are now on May 6th, when Redcare Pharmacy will release its complete quarterly figures. The newly formed executive team must then demonstrate that the explosive growth in prescription sales is a sustainable trend capable of justifying the massive logistics investments and setting the company on a path to improved profitability.